Potentially great news for folks suffering from MS:
"A trial has shown [that Gilenya] not only cuts the risk of an MS attack, it can also slow brain shrinkage, which otherwise can occur in patients at three times the normal rate."
Gilenya, aka fingolimod, is already in use to help both treat (and sometmes prevent) symptoms, and to slow down the damage that MS can cause. This new study "showed the drug cut the risk of an attack by up to 60 per cent and brain shrinkage by 35 to 39 per cent."
That's a significant reduction in both areas, and provides fresh hope in the fight against this ravaging disease.
"A trial has shown [that Gilenya] not only cuts the risk of an MS attack, it can also slow brain shrinkage, which otherwise can occur in patients at three times the normal rate."
Gilenya, aka fingolimod, is already in use to help both treat (and sometmes prevent) symptoms, and to slow down the damage that MS can cause. This new study "showed the drug cut the risk of an attack by up to 60 per cent and brain shrinkage by 35 to 39 per cent."
That's a significant reduction in both areas, and provides fresh hope in the fight against this ravaging disease.
0 komentar:
Posting Komentar